28 research outputs found

    Abortion Providers and the New Regulatory Regime: The Impact of Extreme Reproductive Governance on Abortion Care in the United States

    Get PDF
    This article discusses the impact of the recent wave of abortion restrictions on abortion provision in the United States, a phenomenon that has led to the closing of numerous clinics. The article offers some context of the political forces that led to this expansion of restrictions, and describes two of the most consequential ones: Ambulatory Surgi-Center (ASC) requirements, which dictate that clinics conform to the physical specifications of small hospitals; and hospital-admitting privileges ones, which mandate that doctors providing abortions obtain privileges at local hospitals. I draw on research I have conducted with abortion providers in nine “red” or conservative states that have imposed new restrictions or intensified the monitoring of existing ones. I show how responding to this new regulatory environment, which includes a greatly intensified schedule of surprise inspections, has consequences for the daily operations of the clinic, for the morale of both staff and patients, and for senior staff’s ability to sustain and transmit to junior staff their original vision of woman-centered care. I conclude by suggesting that the current regulatory regime governing abortion care in many states represents an extreme example of “reproductive governance,” a recent concept in the social science literature on reproduction.Cet article explore comment la rĂ©cente vague de restrictions lĂ©gislatives en matiĂšre d’avortement a conduit Ă  la fermeture de nombreuses cliniques. L’article examine comment contexte politique a favorisĂ© l’essor de ce type de mesures. Il se penche Ă©galement sur l’exemple de deux de ces mesures dont l’impact a Ă©tĂ© consĂ©quent : la premiĂšre requiert que les cliniques pratiquant des avortements se conforment aux normes demandĂ©es pour un centre de chirurgie ambulatoire (ambulatory surgical center), la seconde exige que les mĂ©decins pratiquant des avortements soient autorisĂ©s Ă  admettre leurs patients dans un hĂŽpital proche (admitting privileges).Il s’appuie sur des recherches menĂ©es auprĂšs de cliniques qui pratiquent des avortements dans neuf Ă©tats « rouges », autrement dit conservateurs, ayant imposĂ© de nouvelles restrictions ou ayant intensifiĂ© l’application des mesures dĂ©jĂ  existantes. Il dĂ©montre que s’adapter Ă  ce climat de rĂ©gulation, qui a eu pour effet d’intensifier le rythme des inspections surprises, a des consĂ©quences certaines sur le quotidien d’une clinique, sur le moral du personnel et des patients, sur la capacitĂ© des mĂ©decins expĂ©rimentĂ©s Ă  fournir une qualitĂ© de soin axĂ©e sur les patientes tout en transmettant ce modĂšle Ă  leurs jeunes collĂšgues. Il suggĂšre en conclusion que le systĂšme actuel de rĂ©gulation qui rĂ©git la prise en charge des avortements dans de nombreux États est un exemple, poussĂ© Ă  l’extrĂȘme, de « contrĂŽle reproductif », concept Ă©mergent en recherche en science sociale sur la reproduction

    Training Genetic Counsellors to Deliver an Innovative Therapeutic Intervention: their views and experience of facilitating multi-family discussion groups

    Get PDF
    Innovations in clinical genetics have increased diagnosis, treatment and prognosis of inherited genetic conditions (IGCs). This has led to an increased number of families seeking genetic testing and / or genetic counselling and increased the clinical load for genetic counsellors (GCs). Keeping pace with biomedical discoveries, interventions are required to support families to understand, communicate and cope with their Inherited Genetic Condition. The Socio-Psychological Research in Genomics (SPRinG) collaborative have developed a new intervention, based on multi-family discussion groups (MFDGs), to support families affected by IGCs and train GCs in its delivery. A potential challenge to implementing the intervention was whether GCs were willing and able to undergo the training to deliver the MFDG. In analysing three multi-perspective interviews with GCs, this paper evaluates the training received. Findings suggests that MFDGs are a potential valuable resource in supporting families to communicate genetic risk information and can enhance family function and emotional well-being. Furthermore, we demonstrate that it is feasible to train GCs in the delivery of the intervention and that it has the potential to be integrated into clinical practice. Its longer term implementation into routine clinical practice however relies on changes in both organisation of clinical genetics services and genetic counsellors' professional development

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    Abortion as single-issue politics

    No full text

    Abortion Politics

    No full text

    Normalizing the exceptional: incorporating the "abortion pill" into mainstream medicine

    No full text
    Mifepristone, also known as RU-486, and in the US known as "the French abortion pill", finally received FDA approval in the United States in September 2000. This paper discusses the steps now in process to integrate this drug into mainstream healthcare and the sociological implications of those efforts. Each of the steps that is normally taken to introduce a newly approved medication in the US context is rendered highly complex in the case of mifepristone--because of the unique circumstances of abortion in both American culture generally, and medical culture specifically. The story of RU-486/mifepristone, as it is currently unfolding, can be understood as one of attempting to "normalize the exceptional". After offering a brief historical overview of the protracted struggle for FDA approval of mifepristone in the US, this paper discusses the typical processes for integration of a newly approved medication into mainstream medicine and contrasts this process with the special challenges posed by a drug that is associated with abortion. We outline the challenges to implementation, including both external and internal obstacles. We compare the traditional role of a pharmaceutical company in drug diffusion and the circumstances of the company that produces mifepristone in the US. We discuss such external obstacles as the conflict between the FDA-approved regime and an evidence-based alternative; the necessity for physicians to order and dispense this drug; the ambiguity over the need for ultrasonography; and insurance reimbursement, malpractice, and other legal issues. Internal issues addressed include "turf issues" between medical specialties and between physicians and advanced practice clinicians as well as concerns over "cowboy medicine", and patient compliance. This paper concludes with an exploration of the sociological implications of this effort to "normalize the exceptional".Abortion Mifepristone Technological diffusion United States
    corecore